1 | A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. (Bartlett NL, Herrera AF, Domingo-Domenech E, Mehta A, Forero-Torres A, Garcia-Sanz R, Armand P, Devata S, Izquierdo AR, Lossos IS, Reeder C, Sher T, Chen R, Schwarz SE, Alland L, Strassz A, Prier K, Choe-Juliak C, Ansell SM) Blood 2020 Nov 19;136(21):2401-2409 87 Citations |
1 | Observational study of recombinant factor VIII-Fc, rFVIIIFc, in hemophilia A. (Ebbert PT, Xavier F, Malec LM, Seaman CD, Ragni MV) Thromb Res 2020 Nov;195:51-54 6 Citations |
1 | The impact of extended half-life factor concentrates on prophylaxis for severe hemophilia in the United States. (Malec LM, Cheng D, Witmer CM, Jaffray J, Kouides PA, Haley KM, Sidonio RF Jr, Johnson K, Recht M, White G, Croteau SE, Ragni MV) Am J Hematol 2020 Aug;95(8):960-965 17 Citations |
1 | Spontaneous bleeding and poor bleeding response with extended half-life factor IX products: A survey of select US haemophilia treatment centres. (Malec LM, Croteau SE, Callaghan MU, Sidonio RF Jr) Haemophilia 2020 May;26(3):e128-e129 17 Citations |
1 | A phase 2 study to assess the pharmacokinetics and pharmacodynamics of CPX-351 and its effects on cardiac repolarization in patients with acute leukemias. (Lin TL, Newell LF, Stuart RK, Michaelis LC, Rubenstein E, Pentikis HS, Callahan T, Alvarez D, Liboiron BD, Mayer LD, Wang Q, Banerjee K, Louie AC) Cancer Chemother Pharmacol 2019 Jul;84(1):163-173 8 Citations |
1 | Regional variation and cost implications of prescribed extended half-life factor concentrates among U.S. Haemophilia Treatment Centres for patients with moderate and severe haemophilia. (Croteau SE, Cheng D, Cohen AJ, Holmes CE, Malec LM, Silvey M, Thornburg CD, Wheeler AP, Kouides PA, Raffini LJ, Neufeld EJ) Haemophilia 2019 Jul;25(4):668-675 34 Citations |
1 | Discovery of Novel Pyruvate Dehydrogenase Kinase 4 Inhibitors for Potential Oral Treatment of Metabolic Diseases. (Lee D, Pagire HS, Pagire SH, Bae EJ, Dighe M, Kim M, Lee KM, Jang YK, Jaladi AK, Jung KY, Yoo EK, Gim HE, Lee S, Choi WI, Chi YI, Song JS, Bae MA, Jeon YH, Lee GH, Liu KH, Lee T, Park S, Jeon JH, Lee IK, Ahn JH) J Med Chem 2019 Jan 24;62(2):575-588 18 Citations |
1 | The endothelial cell receptor stabilin-2 regulates VWF-FVIII complex half-life and immunogenicity. (Swystun LL, Lai JD, Notley C, Georgescu I, Paine AS, Mewburn J, Nesbitt K, Schledzewski K, Géraud C, Kzhyshkowska J, Goerdt S, Hopman W, Montgomery RR, James PD, Lillicrap D) J Clin Invest 2018 Aug 31;128(9):4057-4073 57 Citations |
1 | Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. (Wenzler E, Bleasdale SC, Sikka M, Bunnell KL, Finnemeyer M, Rosenkranz SL, Danziger LH, Rodvold KA, Antibacterial Resistance Leadership Group) Antimicrob Agents Chemother 2018 Aug;62(8) 26 Citations |
1 | NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease. (Field JJ, Majerus E, Ataga KI, Vichinsky EP, Schaub R, Mashal R, Nathan DG) PLoS One 2017;12(2):e0171067 26 Citations |
1 | Extended half-life factor VIII for immune tolerance induction in haemophilia. (Malec LM, Journeycake J, Ragni MV) Haemophilia 2016 Nov;22(6):e552-e554 26 Citations |
1 | Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A. (Pipe SW, Montgomery RR, Pratt KP, Lenting PJ, Lillicrap D) Blood 2016 Oct 20;128(16):2007-2016 145 Citations |
1 | PIAS1 Promotes Lymphomagenesis through MYC Upregulation. (Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP) Cell Rep 2016 Jun 07;15(10):2266-2278 35 Citations |
1 | Green tea component epigallocatechin-3-gallate decreases expression of osteopontin via a decrease in mRNA half-life in cell lines of metastatic hepatocellular carcinoma. (Zapf MA, Kothari AN, Weber CE, Arffa ML, Wai PY, Driver J, Gupta GN, Kuo PC, Mi Z) Surgery 2015 Oct;158(4):1039-47; discussion 1047-8 14 Citations |
1 | Kinetics of phytosterol metabolism in neonates receiving parenteral nutrition. (Nghiem-Rao TH, Tunc I, Mavis AM, Cao Y, Polzin EM, Firary MF, Wang X, Simpson PM, Patel SB) Pediatr Res 2015 Aug;78(2):181-9 19 Citations |
1 | Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance. (Ragni MV, Malec LM) Expert Rev Hematol 2014 Dec;7(6):747-55 18 Citations |
1 | Effect of dehusked Garcinia kola seeds on the overall pharmacokinetics of quinine in healthy Nigerian volunteers. (Igbinoba SI, Onyeji CO, Akanmu MA, Soyinka JO, Pullela SS, Cook JM, Nathaniel TI) J Clin Pharmacol 2015 Mar;55(3):348-54 8 Citations |
1 | Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. (Bendell JC, Hong DS, Burris HA 3rd, Naing A, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R) Cancer Chemother Pharmacol 2014 Jul;74(1):125-30 89 Citations |
4 | Factors that influence parathyroid hormone half-life: determining if new intraoperative criteria are needed. (Leiker AJ, Yen TW, Eastwood DC, Doffek KM, Szabo A, Evans DB, Wang TS) JAMA Surg 2013 Jul;148(7):602-6 60 Citations |
1 | Glycosylation-independent lysosomal targeting of acid α-glucosidase enhances muscle glycogen clearance in pompe mice. (Maga JA, Zhou J, Kambampati R, Peng S, Wang X, Bohnsack RN, Thomm A, Golata S, Tom P, Dahms NM, Byrne BJ, LeBowitz JH) J Biol Chem 2013 Jan 18;288(3):1428-38 84 Citations |
2 | A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. (Hanson MS, Xu H, Flewelen TC, Holzhauer SL, Retherford D, Jones DW, Frei AC, Pritchard KA Jr, Hillery CA, Hogg N, Wandersee NJ) Am J Physiol Heart Circ Physiol 2013 Jan 15;304(2):H328-36 11 Citations |
1 | Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. (Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA) Lancet Oncol 2012 Aug;13(8):773-81 453 Citations |
1 | Pharmacokinetics of acetaminophen-protein adducts in adults with acetaminophen overdose and acute liver failure. (James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee WM) Drug Metab Dispos 2009 Aug;37(8):1779-84 143 Citations |
1 | Acetaminophen-associated hepatic injury: evaluation of acetaminophen protein adducts in children and adolescents with acetaminophen overdose. (James LP, Capparelli EV, Simpson PM, Letzig L, Roberts D, Hinson JA, Kearns GL, Blumer JL, Sullivan JE, Network of Pediatric Pharmacology Research Units, National Institutes of Child Health and Human Development) Clin Pharmacol Ther 2008 Dec;84(6):684-90 63 Citations |
1 | Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). (Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG, Montgomery RR) Blood 2008 May 15;111(10):4979-85 135 Citations |
1 | Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. (Haberichter SL, Balistreri M, Christopherson P, Morateck P, Gavazova S, Bellissimo DB, Manco-Johnson MJ, Gill JC, Montgomery RR) Blood 2006 Nov 15;108(10):3344-51 167 Citations |
1 | Phase I study of a novel recombinant human soluble thrombomodulin, ART-123. (Moll S, Lindley C, Pescatore S, Morrison D, Tsuruta K, Mohri M, Serada M, Sata M, Shimizu H, Yamada K, White GC 2nd) J Thromb Haemost 2004 Oct;2(10):1745-51 77 Citations |
1 | Spin traps: in vitro toxicity and stability of radical adducts. (Khan N, Wilmot CM, Rosen GM, Demidenko E, Sun J, Joseph J, O'Hara J, Kalyanaraman B, Swartz HM) Free Radic Biol Med 2003 Jun 01;34(11):1473-81 111 Citations |
1 | Comparative response of plasma VWF in dogs to up-regulation of VWF mRNA by interleukin-11 versus Weibel-Palade body release by desmopressin (DDAVP). (Olsen EH, McCain AS, Merricks EP, Fischer TH, Dillon IM, Raymer RA, Bellinger DA, Fahs SA, Montgomery RR, Keith JC Jr, Schaub RG, Nichols TC) Blood 2003 Jul 15;102(2):436-41 32 Citations |
1 | Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. (Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G) Cancer Chemother Pharmacol 2002 Dec;50(6):465-72 118 Citations |
1 | Tinea capitis: epidemiology, diagnosis and management strategies. (Pomeranz AJ, Sabnis SS) Paediatr Drugs 2002;4(12):779-83 57 Citations |
1 | Phase I clinical and pharmacokinetic trial of irofulven. (Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H) Cancer Chemother Pharmacol 2001 Dec;48(6):467-72 16 Citations |
2 | Detection of superoxide anion using an isotopically labeled nitrone spin trap: potential biological applications. (Zhang H, Joseph J, Vasquez-Vivar J, Karoui H, Nsanzumuhire C, Martásek P, Tordo P, Kalyanaraman B) FEBS Lett 2000 May 04;473(1):58-62 145 Citations |
1 | Human renin mRNA stability is increased in response to cAMP in Calu-6 cells. (Sinn PL, Sigmund CD) Hypertension 1999 Mar;33(3):900-5 37 Citations |
1 | Ras enhances Myc protein stability. (Sears R, Leone G, DeGregori J, Nevins JR) Mol Cell 1999 Feb;3(2):169-79 387 Citations |
1 | Current guidelines for antibiotic prophylaxis of surgical wounds. (Woods RK, Dellinger EP) Am Fam Physician 1998 Jun;57(11):2731-40 99 Citations |
1 | A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. (White GC 2nd, Courter S, Bray GL, Lee M, Gomperts ED) Thromb Haemost 1997 Apr;77(4):660-7 128 Citations |
1 | Importance of the organ-independent elimination of cisatracurium. (Kisor DF, Schmith VD, Wargin WA, Lien CA, Ornstein E, Cook DR) Anesth Analg 1996 Nov;83(5):1065-71 122 Citations |
1 | The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinolinium diester neuromuscular blocking drug. (Savarese JJ, Lien CA, Belmont MR, Rubin L) Acta Anaesthesiol Scand Suppl 1995;106:18-22 11 Citations |
1 | Protein C survival during replacement therapy in homozygous protein C deficiency. (Marlar RA, Sills RH, Groncy PK, Montgomery RR, Madden RM) Am J Hematol 1992 Sep;41(1):24-31 23 Citations |
1 | Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B. (Kim HC, McMillan CW, White GC, Bergman GE, Saidi P) Semin Hematol 1990 Apr;27(2 Suppl 2):30-5 24 Citations |
1 | Hemophilic patients with an inhibitor to factor VIII treated with high dose factor VIII concentrate. Results of a collaborative study for the evaluation of factor VIII inhibitor titer, recovery and half life of infused factor VIII. (Sultan Y, White GC, Aronstam A, Bosser C, Brackmann HH, Brochier G, Gormsen J, Mariani G, Roberts HR, Scarabin Y) Nouv Rev Fr Hematol (1978) 1986;28(2):85-9 14 Citations |
1 | Pharmacokinetics, single-dose tolerance, and biological activity of recombinant gamma-interferon in cancer patients. (Kurzrock R, Rosenblum MG, Sherwin SA, Rios A, Talpaz M, Quesada JR, Gutterman JU) Cancer Res 1985 Jun;45(6):2866-72 183 Citations |